vs
Hillenbrand, Inc.（HI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Hillenbrand, Inc.的1.4倍（$772.1M vs $550.2M），Revvity净利率更高（12.7% vs -0.4%，领先13.1%），Revvity同比增速更快（5.9% vs -22.2%），Revvity自由现金流更多（$161.8M vs $-31.6M），过去两年Revvity的营收复合增速更高（9.0% vs -16.3%）
希伦布兰德是一家全球化多元化工业企业，设计、生产及销售专用加工设备与耐用工业解决方案，服务食品饮料、农业、制造、废弃物管理等领域，业务覆盖北美、欧洲及亚太地区。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HI vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.4倍
$550.2M
营收增速更快
RVTY
高出28.0%
-22.2%
净利率更高
RVTY
高出13.1%
-0.4%
自由现金流更多
RVTY
多$193.4M
$-31.6M
两年增速更快
RVTY
近两年复合增速
-16.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $550.2M | $772.1M |
| 净利润 | $-2.2M | $98.4M |
| 毛利率 | 33.4% | — |
| 营业利润率 | -2.2% | 14.5% |
| 净利率 | -0.4% | 12.7% |
| 营收同比 | -22.2% | 5.9% |
| 净利润同比 | -134.4% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HIRVTY
| Q4 25 | $550.2M | $772.1M | ||
| Q3 25 | $652.1M | $698.9M | ||
| Q2 25 | $598.9M | $720.3M | ||
| Q1 25 | $715.9M | $664.8M | ||
| Q4 24 | $706.9M | $729.4M | ||
| Q3 24 | $837.6M | $684.0M | ||
| Q2 24 | $786.6M | $691.7M | ||
| Q1 24 | $785.3M | $649.9M |
净利润HIRVTY
| Q4 25 | $-2.2M | $98.4M | ||
| Q3 25 | $75.7M | $46.7M | ||
| Q2 25 | $1.9M | $53.9M | ||
| Q1 25 | $-40.9M | $42.2M | ||
| Q4 24 | $6.4M | $94.6M | ||
| Q3 24 | $14.6M | $94.4M | ||
| Q2 24 | $-248.9M | $55.4M | ||
| Q1 24 | $6.1M | $26.0M |
毛利率HIRVTY
| Q4 25 | 33.4% | — | ||
| Q3 25 | 34.8% | 53.6% | ||
| Q2 25 | 33.8% | 54.5% | ||
| Q1 25 | 33.0% | 56.5% | ||
| Q4 24 | 33.2% | — | ||
| Q3 24 | 34.4% | 56.3% | ||
| Q2 24 | 33.9% | 55.7% | ||
| Q1 24 | 31.9% | 54.6% |
营业利润率HIRVTY
| Q4 25 | -2.2% | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | 1.8% | 12.6% | ||
| Q1 25 | -6.2% | 10.9% | ||
| Q4 24 | 2.2% | 16.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | -32.7% | 12.4% | ||
| Q1 24 | 1.6% | 6.8% |
净利率HIRVTY
| Q4 25 | -0.4% | 12.7% | ||
| Q3 25 | 11.6% | 6.7% | ||
| Q2 25 | 0.3% | 7.5% | ||
| Q1 25 | -5.7% | 6.4% | ||
| Q4 24 | 0.9% | 13.0% | ||
| Q3 24 | 1.7% | 13.8% | ||
| Q2 24 | -31.6% | 8.0% | ||
| Q1 24 | 0.8% | 4.0% |
每股收益（稀释后）HIRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | $1.07 | $0.40 | ||
| Q2 25 | $0.03 | $0.46 | ||
| Q1 25 | $-0.58 | $0.35 | ||
| Q4 24 | $0.09 | $0.77 | ||
| Q3 24 | $0.20 | $0.77 | ||
| Q2 24 | $-3.53 | $0.45 | ||
| Q1 24 | $0.09 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $173.1M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.4B | $7.3B |
| 总资产 | $4.5B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HIRVTY
| Q4 25 | $173.1M | $919.9M | ||
| Q3 25 | $164.8M | $931.4M | ||
| Q2 25 | $162.8M | $991.8M | ||
| Q1 25 | $458.4M | $1.1B | ||
| Q4 24 | $208.0M | $1.2B | ||
| Q3 24 | $199.3M | $1.2B | ||
| Q2 24 | $223.8M | $2.0B | ||
| Q1 24 | $224.4M | $1.7B |
总债务HIRVTY
| Q4 25 | — | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.9B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.1B | — |
股东权益HIRVTY
| Q4 25 | $1.4B | $7.3B | ||
| Q3 25 | $1.4B | $7.4B | ||
| Q2 25 | $1.3B | $7.6B | ||
| Q1 25 | $1.3B | $7.6B | ||
| Q4 24 | $1.4B | $7.7B | ||
| Q3 24 | $1.4B | $7.9B | ||
| Q2 24 | $1.4B | $7.9B | ||
| Q1 24 | $1.7B | $7.8B |
总资产HIRVTY
| Q4 25 | $4.5B | $12.2B | ||
| Q3 25 | $4.5B | $12.1B | ||
| Q2 25 | $4.7B | $12.4B | ||
| Q1 25 | $4.8B | $12.4B | ||
| Q4 24 | $5.1B | $12.4B | ||
| Q3 24 | $5.2B | $12.8B | ||
| Q2 24 | $5.3B | $13.4B | ||
| Q1 24 | $5.6B | $13.4B |
负债/权益比HIRVTY
| Q4 25 | — | — | ||
| Q3 25 | 1.10× | — | ||
| Q2 25 | 1.27× | — | ||
| Q1 25 | 1.44× | — | ||
| Q4 24 | 1.38× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.48× | — | ||
| Q1 24 | 1.28× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-27.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-31.6M | $161.8M |
| 自由现金流率自由现金流/营收 | -5.7% | 21.0% |
| 资本支出强度资本支出/营收 | 0.8% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $7.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流HIRVTY
| Q4 25 | $-27.4M | $182.0M | ||
| Q3 25 | $67.7M | $138.5M | ||
| Q2 25 | $-1.5M | $134.3M | ||
| Q1 25 | $1.3M | $128.2M | ||
| Q4 24 | $-11.3M | $174.2M | ||
| Q3 24 | $166.5M | $147.9M | ||
| Q2 24 | $45.6M | $158.6M | ||
| Q1 24 | $3.2M | $147.6M |
自由现金流HIRVTY
| Q4 25 | $-31.6M | $161.8M | ||
| Q3 25 | $58.6M | $120.0M | ||
| Q2 25 | $-11.2M | $115.5M | ||
| Q1 25 | $-8.0M | $112.2M | ||
| Q4 24 | $-21.5M | $149.8M | ||
| Q3 24 | $153.4M | $125.6M | ||
| Q2 24 | $29.7M | $136.6M | ||
| Q1 24 | $-9.6M | $129.7M |
自由现金流率HIRVTY
| Q4 25 | -5.7% | 21.0% | ||
| Q3 25 | 9.0% | 17.2% | ||
| Q2 25 | -1.9% | 16.0% | ||
| Q1 25 | -1.1% | 16.9% | ||
| Q4 24 | -3.0% | 20.5% | ||
| Q3 24 | 18.3% | 18.4% | ||
| Q2 24 | 3.8% | 19.7% | ||
| Q1 24 | -1.2% | 20.0% |
资本支出强度HIRVTY
| Q4 25 | 0.8% | 2.6% | ||
| Q3 25 | 1.4% | 2.6% | ||
| Q2 25 | 1.6% | 2.6% | ||
| Q1 25 | 1.3% | 2.4% | ||
| Q4 24 | 1.4% | 3.4% | ||
| Q3 24 | 1.6% | 3.3% | ||
| Q2 24 | 2.0% | 3.2% | ||
| Q1 24 | 1.6% | 2.7% |
现金转化率HIRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 0.89× | 2.97× | ||
| Q2 25 | -0.79× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | -1.77× | 1.84× | ||
| Q3 24 | 11.40× | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | 0.52× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HI
| Transferred At Point In Time | $256.5M | 47% |
| Transferred Over Time | $207.1M | 38% |
| Molding Technology Solutions | $86.6M | 16% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
